Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, Stempora L, Hammond C, Wouters A, Mojcik CF, Cheng J, Collinge M, Jesson MI, Hazra A, Biswas P, Lan S, Clark JD, Hodge JA.
Weinhold KJ, et al. Among authors: mojcik cf.
Clin Immunol. 2018 Jun;191:10-20. doi: 10.1016/j.clim.2018.03.002. Epub 2018 Mar 5.
Clin Immunol. 2018.
PMID: 29518577
Free PMC article.
Clinical Trial.